生命科学资讯

CLIM-TIME identifies metastatic microenvironment modulators for T cell therapy response

Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial

BridgeBio preps approval push after dwarfism drug increases children's height in phase 3

Langer-backed biotech looks to end cancer recurrence with surgical revolution

Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval

Seres to lay off 30% of employees, pause lead program in latest strategic shift

A pancreatic cancer approval; Seres cuts staff

Even Europeans don't see a future in Euro biopharma anymore

Agilent Technologies, Inc. (NYSE:A) to Issue $0.26 Quarterly Dividend - MarketBeat

Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval - Fierce Biotech

ING Groep NV Has $15.53 Million Position in Thermo Fisher Scientific Inc. $TMO - MarketBeat

Terray says its AI model beats Boltz-2 at binding affinity prediction

Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift

Lyell starts first head-to-head CAR-T therapy trial

Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips - Zacks Investment Research

BridgeBio's dwarfism drug succeeds in Phase 3, adding to recent late-stage wins

BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis

10x Genomics PharosAI Cancer Project Tests Xenium’s Long Term Investment Case - Yahoo Finance

Sanofi ousts Paul Hudson after ‘bumpy ride’, poaches Merck KGaA CEO to lead the French pharma

European VCs join forces to boost flagging biotech investment in the region